Sanofi Pasteur and Butantan Institute to Provide A(H1N1) Vaccine to Brazilian Government
Initial supply of 18 million doses of A(H1N1) influenza vaccine
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced it has signed an agreement with Butantan Institute for the production and supply of a vaccine against the novel A(H1N1) influenza virus for the Brazilian Government. This contract was announced during a state visit to Brazil by French President Nicolas Sarkozy.
The order from the Brazilian Ministry of Health provides for the initial supply of 18 million doses of the new A(H1N1) influenza virus vaccine: one million doses in final presentation and 17 million doses in bulk form. The agreement includes an option for an additional 15 million doses of A(H1N1) vaccine should the World Health Organization (WHO) request influenza manufacturers to switch production from the regular Southern Hemisphere Seasonal influenza vaccine to the Pandemic A(H1N1) vaccine.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
A Trojan Horse delivery for treating a rare, potentially deadly, blood-clotting disorder - In this possible treatment, platelet blood cells carry an enzyme needed to prevent clots in TTP, while hiding the enzyme from autoantibody neutralization
CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
Novel HCMV compound of AiCuris in phase IIb trial with bone marrow transplant recipients
Basilea receives milestone payment from distribution agreement for Toctino with Almirall
Biotage AB and McMaster University sign joint agreement to develop new chemistry platform
Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan
Pharmacogenomics study finds rare gene variants critical for personalized drug treatment

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection
Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition
Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology
